Status:
COMPLETED
Head to Head Study Against Sevelamer Hydrochloride
Lead Sponsor:
Shire
Conditions:
Chronic Kidney Disease, Stage 5
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
To compare the efficacy of Fosrenol (Lanthanum carbonate) and sevelamer hydrochloride in the reduction of serum phosphorus levels from baseline.
Detailed Description
To compare the efficacy of Fosrenol (Lanthanum carbonate) and sevelamer hydrochloride in the reduction of serum phosphorus levels from baseline.
Eligibility Criteria
Inclusion
- Adults with end stage renal disease who are receiving dialysis
Exclusion
- Subjects with significant gastrointestinal disorders
- Subjects who are pregnant or nursing
- Subjects currently taking lanthanum carbonate, sevelamer hydrochloride, cinacalcet hydrochloride
- Subjects who are HIV positive
- Subjects with clinical significant liver disease
Key Trial Info
Start Date :
January 5 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 31 2008
Estimated Enrollment :
182 Patients enrolled
Trial Details
Trial ID
NCT00441545
Start Date
January 5 2007
End Date
July 31 2008
Last Update
June 11 2021
Active Locations (44)
Enter a location and click search to find clinical trials sorted by distance.
1
DSI Renal Inc.
Mesa, Arizona, United States, 85202
2
AKDHC Medical Research Services, LLC
Phoenix, Arizona, United States, 85012
3
Southwest Kidney Institute, PLC
Tempe, Arizona, United States, 85284
4
Tempe, Arizona, United States, 85284